News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UCB Pharma (UCBJF.PK) To Test Arthritis Drug Cimzia Against Abbott Laboratories (ABT)'s Humira


5/26/2011 6:52:02 AM

Belgian pharmaceutical company UCB SA (UCB.BT) Wednesday said it will test its flagship rheumatoid arthritis drug Cimzia in a head-to-head clinical trial against Abbott Laboratories' (ABT) anti-inflammatory drug Humira.

UCB hopes the trial will reflect well on Cimzia, which had sales last year of EUR198 million (about $280 million) and is one of three core products on which the Belgium-based drug maker is betting to boost sales, offsetting the loss of patents on older blockbusters.

"We believe the study will provide additional evidence that the ability to make an informed and early treatment decision is important for the treatment of this severe and progressing disease," UCB's chief medical officer Iris Loew-Friedrich said in a statement.



comments powered by Disqus
UCB Pharma
Abbott
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES